Evidence map›Paper›PMID 36326979›Full record

ArticleEuropean journal of epidemiology2022

Zinc supplement use and risk of aggressive prostate cancer: a 30-year follow-up study.

Yiwen Zhang, Mingyang Song, Lorelei A Mucci, Edward L Giovannucci

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in European journal of epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07367412 (Effect of Zinc Supplementation on Occurrence of Infections in Older Medical Patients), which is not on this map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07367412 narecruitingnot on this mapstarted 2026, after this paper: background citation

Effect of Zinc Supplementation on Occurrence of Infections in Older Medical Patients (ZOOM) - a Cluster Randomized Controlled Trial (ZOOM OUT).

TypeinterventionalSponsorHerlev HospitalRan2026 to 2028Enrolled8,000ConditionsOlder Adults (65 Years and Older), Medical Patients in the Emergency DepartmentArmsZinc (zinc sulphate)
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Coordination chemistry suggests that independently observed benefits of metformin and ZnBiometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024
    Article
  11. Review
  12. Appendectomy and Risk of Prostate Cancer in the Health Professionals Follow-up Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article
  13. Zinc Toxicity: Understanding the Limits.Molecules (Basel, Switzerland) · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yiwen ZhangDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Mingyang SongClinical and Translational Epidemiology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Lorelei A MucciDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Edward L GiovannucciDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA. egiovann@hsph.harvard.edu.ORCID http://orcid.org/0000-0002-6123-0219
Harvard University · US

Funding

Cancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0M
NCI NIH HHS U01 CA167552NIH HHS U01 CA167552
6 · The paper itself

Abstract

backgroundZinc supplementation was hypothesized to have therapeutic potential against prostate cancer, but its influence on prostate cancer incidence especially at high doses is controversial.

methodsA total of 47,240 men from the Health Professionals Follow-up Study were followed from 1986 to 2016. Men reported their zinc supplement use at baseline and biennially thereafter. Clinical features of prostate cancer included stage, grade, lethal and aggressive (T4 or N1 or M1 or Gleason 8-10) outcome. Multivariable Cox proportional hazards models were used to evaluate the association between zinc supplement use and incidence of prostate cancer.

resultsDuring a median follow-up of 28.3 years, we documented 6,980 incident prostate cancer cases including 1,053 lethal and 1,143 aggressive. Zinc supplement use was not associated with overall, localized, low- and intermediate-grade prostate cancer. However, compared to never-users, men who used supplement zinc more than 75 mg/day were at higher risk for lethal (HR: 1.76, 95% CI: 1.16-2.66, P

conclusionZinc supplementation of more than 75 mg per day or over 15 years may substantially increase risk of lethal and aggressive prostate cancer. Caution is warranted regarding excessive usage of zinc supplements among adult men.

Indexed as

Prostatic NeoplasmsAdultDietary SupplementsFollow-Up StudiesHumansMaleProportional Hazards ModelsRisk FactorsZincZincCohort studyDietary supplementProstate cancerZinc

Identifiers

PMID36326979
PMCPMC9630799
OpenAlexW4308257023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.